Drugs / CMTS4520
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06839599 | Feb 2025 → Jan 2030 expected | diarrheal disease | The Second Hospital of Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06839586 | Feb 2025 → Jan 2030 expected | chronic diarrheal disease | The Second Hospital of Nanjing Medical University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMTS4520 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06839599 ↗ |
| Modality | Other / unclassified | “CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains.” NCT06839586 ↗ |